Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
Globe Newswire•29/09/2026•17:50 ET
0
Key Highlights
- ➤Poster presentation covers long-term open-label rexaceract data in Parkinson’s disease
- ➤Presentation scheduled October 7, 2026, at International Congress in Seoul
- ➤Rexaceract currently evaluated in Phase 1b trial for Parkinson’s disease
- ➤Phase 1b extension allows rexaceract treatment for up to 12 months
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea.
Poster Title: Long-Term Open-Label Data on the GCase Modulator GT-02287 (Rexaceract) in People with Parkinson’s Disease
Get started
Create a free account to read the full story.